{"id":64338,"date":"2026-04-30T15:25:50","date_gmt":"2026-04-30T07:25:50","guid":{"rendered":"https:\/\/flcube.com\/?p=64338"},"modified":"2026-04-30T15:25:51","modified_gmt":"2026-04-30T07:25:51","slug":"beone-medicines-tislelizumab-zanidatamab-combo-receives-fda-priority-review-for-her2-positive-gastric-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64338","title":{"rendered":"BeOne Medicines&#8217; Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer"},"content":{"rendered":"\n<p><strong>BeOne Medicines Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/ONC:NASDAQ\">NASDAQ: ONC<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/6160:HKG\">HKG: 6160<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/688235:SHA\">SHA: 688235<\/a>), formerly BeiGene, announced that the <strong>U.S. Food and Drug Administration (FDA)<\/strong> has granted <strong>priority review<\/strong> for a new indication filing of its <strong>Tevimbra (tislelizumab)<\/strong> combined with <strong>Ziihera (zanidatamab)<\/strong> as <strong>first-line treatment<\/strong> for <strong>locally advanced unresectable or metastatic HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma (GEA)<\/strong>. The FDA also awarded <strong>zanidatamab breakthrough therapy designation (BTD)<\/strong> for use with chemotherapy in the same indication.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestones\">Regulatory Milestones<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>U.S. Food and Drug Administration (FDA)<\/td><\/tr><tr><td><strong>Priority Review<\/strong><\/td><td>Tevimbra + Ziihera combination for first-line HER2-positive GEA<\/td><\/tr><tr><td><strong>Breakthrough Therapy Designation<\/strong><\/td><td>Zanidatamab + chemotherapy (\u00b1 tislelizumab) for HER2-positive GEA<\/td><\/tr><tr><td><strong>PDUFA Timeline<\/strong><\/td><td>Priority review typically 6 months from filing acceptance<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Locally advanced unresectable or metastatic HER2-positive gastric\/gastroesophageal\/esophageal adenocarcinoma<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>First-line treatment setting<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-tevimbra-tislelizumab\">Tevimbra (tislelizumab)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism<\/strong>: Anti-programmed cell death protein-1 (PD-1) monoclonal antibody<\/li>\n\n\n\n<li><strong>Approval Status<\/strong>: Approved in multiple regions worldwide across various oncology indications<\/li>\n\n\n\n<li><strong>Role in Combination<\/strong>: Immune checkpoint inhibition to enhance anti-tumor immune response<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-ziihera-zanidatamab\">Ziihera (zanidatamab)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism<\/strong>: <strong>Humanized bispecific antibody<\/strong> targeting <strong>HER2<\/strong> with binding to <strong>two non-overlapping extracellular epitopes<\/strong><\/li>\n\n\n\n<li><strong>Innovation<\/strong>: Dual HER2 binding creates enhanced receptor internalization and anti-tumor activity compared to single-epitope antibodies<\/li>\n\n\n\n<li><strong>Development Partnership<\/strong>: Originally developed by Zymeworks, now part of BeOne&#8217;s strategic portfolio<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-data-herizon-gea-01-phase-iii-study\">Clinical Data \u2013 HERIZON-GEA-01 Phase III Study<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Result<\/th><\/tr><\/thead><tbody><tr><td><strong>Study Design<\/strong><\/td><td>Phase III randomized controlled trial<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Locally advanced unresectable or metastatic HER2-positive GEA<\/td><\/tr><tr><td><strong>Treatment Arm<\/strong><\/td><td>Tislelizumab + zanidatamab + chemotherapy<\/td><\/tr><tr><td><strong>Control Arm<\/strong><\/td><td>Trastuzumab + chemotherapy<\/td><\/tr><tr><td><strong>Median Overall Survival (OS)<\/strong><\/td><td><strong>26.4 months<\/strong> (treatment arm)<\/td><\/tr><tr><td><strong>Statistical Significance<\/strong><\/td><td>Significant improvement vs. control arm<\/td><\/tr><tr><td><strong>Therapeutic Impact<\/strong><\/td><td>Represents meaningful advance over current standard of care<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-competitive-landscape\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Analysis<\/th><\/tr><\/thead><tbody><tr><td><strong>HER2-Positive GEA Prevalence<\/strong><\/td><td>Approximately 15-20% of gastric\/gastroesophageal cancers are HER2-positive<\/td><\/tr><tr><td><strong>Current Standard of Care<\/strong><\/td><td>Trastuzumab + chemotherapy established since 2010 with median OS ~13-16 months<\/td><\/tr><tr><td><strong>Unmet Need<\/strong><\/td><td>Limited progress in first-line HER2-positive GEA despite decade-long standard<\/td><\/tr><tr><td><strong>Competitive Differentiation<\/strong><\/td><td>First triple combination demonstrating &gt;26-month median OS in this patient population<\/td><\/tr><tr><td><strong>Market Opportunity<\/strong><\/td><td>Estimated $1.5-2.0 billion global market potential for improved HER2-positive GEA therapy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications-amp-commercial-outlook\">Strategic Implications &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Portfolio Synergy<\/strong>: Leverages BeOne&#8217;s established PD-1 franchise with novel bispecific antibody innovation<\/li>\n\n\n\n<li><strong>Regulatory Momentum<\/strong>: Dual designations (priority review + BTD) accelerate path to market approval<\/li>\n\n\n\n<li><strong>Global Potential<\/strong>: Strong Phase III data supports international regulatory filings beyond U.S. market<\/li>\n\n\n\n<li><strong>Commercial Infrastructure<\/strong>: BeOne&#8217;s existing oncology commercial team can rapidly deploy upon approval<\/li>\n\n\n\n<li><strong>Standard of Care Disruption<\/strong>: Potential to establish new first-line treatment paradigm for HER2-positive GEA<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory timelines, clinical outcomes, and commercial potential. Actual results may differ due to risks including FDA review outcomes, competitive developments, and market adoption dynamics in the gastrointestinal oncology space.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), formerly BeiGene, announced that the U.S&#8230;.<\/p>\n","protected":false},"author":1,"featured_media":64341,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[2092,29,847,28,3046,18,80,848],"class_list":["post-64338","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-beone-medicines","tag-combination-therapy","tag-hkg-6160","tag-multi-specific-antibodies","tag-nasdaq-onc","tag-pd-1-l1","tag-priority-reviews","tag-sha-688235"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>BeOne Medicines&#039; Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), formerly BeiGene, announced that the U.S. Food and Drug Administration (FDA) has granted priority review for a new indication filing of its Tevimbra (tislelizumab) combined with Ziihera (zanidatamab) as first-line treatment for locally advanced unresectable or metastatic HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma (GEA). The FDA also awarded zanidatamab breakthrough therapy designation (BTD) for use with chemotherapy in the same indication.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64338\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BeOne Medicines&#039; Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer\" \/>\n<meta property=\"og:description\" content=\"BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), formerly BeiGene, announced that the U.S. Food and Drug Administration (FDA) has granted priority review for a new indication filing of its Tevimbra (tislelizumab) combined with Ziihera (zanidatamab) as first-line treatment for locally advanced unresectable or metastatic HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma (GEA). The FDA also awarded zanidatamab breakthrough therapy designation (BTD) for use with chemotherapy in the same indication.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64338\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-30T07:25:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-30T07:25:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/3006.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64338#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64338\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"BeOne Medicines&#8217; Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer\",\"datePublished\":\"2026-04-30T07:25:50+00:00\",\"dateModified\":\"2026-04-30T07:25:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64338\"},\"wordCount\":468,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64338#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/3006.webp\",\"keywords\":[\"BeOne Medicines\",\"Combination therapy\",\"HKG: 6160\",\"Multi-specific antibodies\",\"NASDAQ: ONC\",\"PD-1\\\/L1\",\"Priority reviews\",\"SHA: 688235\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64338#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64338\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64338\",\"name\":\"BeOne Medicines' Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64338#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64338#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/3006.webp\",\"datePublished\":\"2026-04-30T07:25:50+00:00\",\"dateModified\":\"2026-04-30T07:25:51+00:00\",\"description\":\"BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), formerly BeiGene, announced that the U.S. Food and Drug Administration (FDA) has granted priority review for a new indication filing of its Tevimbra (tislelizumab) combined with Ziihera (zanidatamab) as first-line treatment for locally advanced unresectable or metastatic HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma (GEA). The FDA also awarded zanidatamab breakthrough therapy designation (BTD) for use with chemotherapy in the same indication.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64338#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64338\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64338#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/3006.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/3006.webp\",\"width\":1080,\"height\":608,\"caption\":\"BeOne Medicines' Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64338#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BeOne Medicines&#8217; Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BeOne Medicines' Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), formerly BeiGene, announced that the U.S. Food and Drug Administration (FDA) has granted priority review for a new indication filing of its Tevimbra (tislelizumab) combined with Ziihera (zanidatamab) as first-line treatment for locally advanced unresectable or metastatic HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma (GEA). The FDA also awarded zanidatamab breakthrough therapy designation (BTD) for use with chemotherapy in the same indication.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64338","og_locale":"en_US","og_type":"article","og_title":"BeOne Medicines' Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer","og_description":"BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), formerly BeiGene, announced that the U.S. Food and Drug Administration (FDA) has granted priority review for a new indication filing of its Tevimbra (tislelizumab) combined with Ziihera (zanidatamab) as first-line treatment for locally advanced unresectable or metastatic HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma (GEA). The FDA also awarded zanidatamab breakthrough therapy designation (BTD) for use with chemotherapy in the same indication.","og_url":"https:\/\/flcube.com\/?p=64338","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-30T07:25:50+00:00","article_modified_time":"2026-04-30T07:25:51+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/3006.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64338#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64338"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"BeOne Medicines&#8217; Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer","datePublished":"2026-04-30T07:25:50+00:00","dateModified":"2026-04-30T07:25:51+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64338"},"wordCount":468,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=64338#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/3006.webp","keywords":["BeOne Medicines","Combination therapy","HKG: 6160","Multi-specific antibodies","NASDAQ: ONC","PD-1\/L1","Priority reviews","SHA: 688235"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64338#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64338","url":"https:\/\/flcube.com\/?p=64338","name":"BeOne Medicines' Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=64338#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=64338#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/3006.webp","datePublished":"2026-04-30T07:25:50+00:00","dateModified":"2026-04-30T07:25:51+00:00","description":"BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), formerly BeiGene, announced that the U.S. Food and Drug Administration (FDA) has granted priority review for a new indication filing of its Tevimbra (tislelizumab) combined with Ziihera (zanidatamab) as first-line treatment for locally advanced unresectable or metastatic HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma (GEA). The FDA also awarded zanidatamab breakthrough therapy designation (BTD) for use with chemotherapy in the same indication.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64338#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64338"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=64338#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/3006.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/3006.webp","width":1080,"height":608,"caption":"BeOne Medicines' Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64338#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"BeOne Medicines&#8217; Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/3006.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64338","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64338"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64338\/revisions"}],"predecessor-version":[{"id":64342,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64338\/revisions\/64342"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/64341"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64338"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64338"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64338"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}